Common fragile sites are specific regions of the genome that form gaps and breaks on metaphase chromosomes when DNA synthesis is partially inhibited. Fragile sites and their associated genes show frequent deletions and other rearrangements in cancer cells, and may be indicators of DNA replication stress early in tumorigenesis. We have previously shown that the DNA damage response proteins ATR, BRCA1 and FANCD2 play critical roles in maintaining the stability of fragile site regions. To further elucidate the pathways regulating fragile site stability, we have investigated the effects of depletion of the cell cycle checkpoint kinases, CHK1 and CHK2 on common fragile site stability in human cells. We demonstrate that both CHK1 and CHK2 are activated following treatment of cells with low doses of aphidicolin that induce fragile site breakage. Furthermore, we show that depletion of CHK1, but not CHK2, using shortinterfering RNA (siRNA) leads to highly destabilized chromosomes and specific common fragile site breakage. In many cells, CHK1 depletion resulted in extensive chromosome fragmentation, which was distinct from endonucleolytic cleavage commonly associated with apoptosis. These findings demonstrate a critical role for the CHK1 kinase in regulating chromosome stability, and in particular, common fragile site stability.
Introduction
Specific chromosomal sites, termed common fragile sites, are particularly susceptible to instability in certain cellular environments. Fragile site regions form gaps and breaks on metaphase chromosomes under conditions of replicative stress, such as those induced by replication inhibitors, including aphidicolin (APH), an inhibitor of DNA polymerases, and also under conditions of folate stress. In addition to gaps and breaks, common fragile sites display a number of characteristics of unstable DNA in cultured cells. Following induction, they are 'hotspots' for increased sister chromatid exchange (SCE), show a high rate of translocations and deletions, and are preferred sites for plasmid and viral integrations (reviewed in Glover et al., 2005) . In addition, common fragile site regions show frequent intra-locus deletions and other rearrangements in cancer cell lines and primary tumors, indicating that these regions are often destabilized during tumorigenesis. The deletions observed at fragile sites, some of which flank or harbor putative tumor suppressor genes such as FHIT at FRA3B and WWOX at FRA16D, could lead to a selective growth advantage, suggesting that fragile site instability may be a contributing factor in cancer initiation and progression (Huang et al., 1999; Mangelsdorf et al., 2000; Ried et al., 2000; Arlt et al., 2002) . Recent evidence of activated cell cycle checkpoint responses and allelic loss at common fragile sites in precancerous lesions suggests that instability at common fragile sites is an indicator of DNA replication stress during early stages of tumorigenesis (Bartkova et al., 2005; Gorgoulis et al., 2005) .
Cells have evolved a number of cell cycle checkpoint signaling pathways that are activated in response to specific types of DNA damage, resulting in either cell cycle delays to allow time for repair, or the induction of apoptosis. The major DNA damage checkpoint protein, Ataxia telangiectasia and Rad3-related kinase (ATR), has been previously established to play a critical role in the maintenance of stability at fragile site regions (Casper et al., 2002) . The ATR-regulated DNA damage response pathway is critical in the response to abnormal replication intermediates and single-stranded DNA generated during replication stalling (Abraham, 2001; Zou and Elledge, 2003) . ATR-deficient cell lines and Seckel syndrome patient-derived cells, which harbor a hypomorphic mutation in ATR, display increased chromosome instability, particularly at fragile sites (Casper et al., 2002 . The ATR targets, BRCA1, FANCD2 and SMC1 have also been shown to be involved in regulating fragile site stability. Howlett et al., 2005; Musio et al., 2005) . The influence of these various replication-stress response proteins on fragile site stability has strengthened the hypothesis that chromosome breakage at fragile sites is the result of stalled or incomplete DNA replication in these regions.
ATR and the related primary DNA damage signal transducer, Ataxia telangiectasia mutated (ATM), directly regulate at least two major effector kinases: CHK1 and CHK2. CHK1 and CHK2 are structurally dissimilar, but have overlapping and partially redundant functions. CHK1 is an evolutionarily conserved checkpoint kinase that is a major downstream target of ATR phosphorylation, and acts as a central regulator of cellcycle checkpoint delays in S-and G2-phases of the cell cycle (Liu et al., 2000; Takai et al., 2000; Bartek and Lukas, 2003) . The CHK2 kinase is typically placed downstream of ATM, although evidence suggests it may also be activated by phosphorylation independently of ATM in some circumstances Hirao et al., 2002) . CHK1 is primarily activated in response to replication stress and stalling during both the S and G2/M cell cycle phases in response to UV and hydroxyurea (HU) while CHK2 is primarily activated by double strand breaks induced by ionizing radiation. Both kinases are phosphorylated and activated during S-phase in response to high-dose APH (Feijoo et al., 2001) . Furthermore, CHK1 was recently shown to have a role in the stabilization of replication structures during S-phase in DT40 B-lymphoma cells (Zachos et al., 2005) . This evidence led us to hypothesize that CHK1, and perhaps CHK2, may respond to replication stress induced by low doses of APH, known to induce fragile site breaks, but not inhibit replication entirely, and that these proteins may regulate common fragile site stability.
Using short-interfering RNAs (siRNAs) targeting CHK1 and CHK2, we depleted cellular CHK1 and CHK2 pools in HCT116 and HeLa cells and examined the effects on total chromosomal stability and on gaps and breaks at the two most common fragile sites, FRA3B and FRA16D, termed 'fragile site expression'. In addition, to address the activation of CHK1 and CHK2 during fragile site expression, we assessed the effects of low doses of APH on the post-translational modification of both CHK1 and CHK2. Both CHK1 and CHK2 were phosphorylated following exposure to low-dose APH. In CHK1-depleted, but not CHK2-depleted, cells we observed a highly significant increase in fragile site expression both spontaneously and following APH treatment, suggesting specific fragile site instability in cells lacking CHK1. In addition, we observed extensive chromosome fragmentation in a subset of cells that was not the result of apoptosisinduced proteolytic degradation. Our findings demonstrate an integral role for CHK1 in regulating fragile site and overall chromosome stability.
Results
Depletion of CHK1 induces chromosome instability and breaks at common fragile sites Using siRNA specific for the CHK1 mRNA, we depleted total cellular CHK1 pools in both HCT116 cervical carcinoma and HeLa colon carcinoma cell lines ( Figure 1a, Supplementary Figure 1a) . Metaphases from CHK1-depleted cells were divided into two subsets based on their degree of chromosomal damage. Metaphases exhibited either a discrete number of quantifiable chromosomal gaps and breaks (Figure 2b and c), defined as less than 100, or severely fragmented, or 'shattered', chromosomes with greater than 100 breaks (Figure 2d ). Approximately 47% of HCT116 and 57% of HeLa cells exhibited this fragmented chromosome phenotype in the absence of APH. This percentage rose to 80 and 96%, respectively, following 24 h treatment with 0.1 mM (HCT116) and 0.3 mM (HeLa) APH (Figure 1b, Supplementary Figure 1b) . In metaphases To determine whether CHK1 depletion specifically results in fragile site instability, expression of the fragile sites FRA3B and FRA16D was examined by FISH using YAC and BAC probes mapping within these regions (Supplementary Figure 2) . Fifty metaphases with positive hybridization of fluorescently labeled probes on both homologs were scored for gaps and breaks at these sites. In CHK1-depleted cells, 4% of HCT116 FRA3B sites and 14% of HeLa FRA3B sites were broken in the absence of aphidicolin, whereas no fragile site breaks were observed in isogenic controls ( Figure 1d, Supplementary Figure 1d ). The magnitude of this breakage increased upon treatment with APH for 24 h. FRA3B breakage rose to 38% in CHK1-depleted HCT116 cells and 83% in CHK1-depleted HeLa cells, an eight to ninefold higher level than those observed in isogenic controls (Figure 1d , Supplementary Figure 1d ), a statistically significant difference (HCT116 Po0.01, HeLa Po0.01). A similar trend was observed with lesions at FRA16D. In cells lacking CHK1, 2% of HCT116 FRA16D sites and 6% of HeLa FRA16D sites were broken. Following 24h APH treatment, FRA16D breaks increased to 30% in CHK1-depleted HCT116 cells and 33% in CHK1-depleted HeLa cells, three to fivefold higher levels than those seen in isogenic controls, a statistically significant difference ( 
To confirm these results, and to rule out the possibility that low levels of CHK2 in RNAi-treated cells were sufficient to maintain fragile site stability, we examined total chromosome and fragile site breakage in the HCT15 colon carcinoma cell line. HCT15 harbors two heterozygous CHK2 missense mutations (R145W and A247D) and expresses functionally inactive CHK2 protein (Lee et al., 2001 ). HCT15 cells did not display a significant difference in spontaneous chromosomal breaks or fragile site breaks in comparison to HCT116 cells transfected with a CHK2-targeting siRNA (Figure 3d -f) consistent with our previous experiments (P ¼ 0.3). HCT116 was chosen for comparison as, like HCT15, it is a colon carcinoma cell line with a diploid karyotype and microsatellite instability and no isogenic CHK2-complemented HCT15 cell line is currently available.
Compound CHK1 and CHK2 deficiency does not result in an additive chromosomal breakage phenotype Recent studies have reported overlapping and partially redundant functions in the roles of CHK1 and CHK2 in response to DNA damage and replication stress (reviewed in Bartek and Lukas, 2003) . To test whether cells lacking both CHK1 and CHK2 had a greater level of chromosomal and fragile site instability than cells lacking only CHK1, we depleted cellular pools of both proteins in HCT116 cells (Supplementary Figure 4a) . Following APH treatment, no statistically significant differences in total chromosome gaps and breaks, shattered metaphases, or fragile site breaks were observed between CHK1-deficient and CHK1-CHK2 deficient HCT116 cells (Supplementary Figure 4b-d) . 
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Extensive chromosomal fragmentation in CHK1-depleted cells is not the result of apoptosis DNA degradation occurs in the late stages of apoptosis, following activation of Ca/Mg dependent endonucleases. To investigate whether the fragmented chromosome phenotype observed in CHK1-depleted cells was a consequence of apoptosis, we examined these cells using early and late stage apoptosis detection assays. CHK1-depleted HCT116 and HeLa cells were analyzed by annexin V staining for phosphatidylserine residues exposed on the outer cytoplasmic cell membrane, an early apoptotic event (Fadok et al., 1992; Tait and Gibson, 1992) (Figure 4a ). Approximately 2% of CHK1-depleted HCT116 cells were found to be apoptotic, the same level as isogenic HCT116 cells transfected with non-targeting siControl RNA (Figure 4b, Supplementary Figure 5) . In contrast, approximately 21% of CHK1-depleted HeLa cells were found to be apoptotic in comparison to 7% of CHK1 proficient cells transfected with a non-targeting siControl RNA, consistent with previously reported findings (Niida et al., 2005; Rodriguez and Meuth, 2005) (Figure 4c, Supplementary Figure 5) . Following 24 h APH treatment, apoptosis levels did not increase significantly in either HCT116 or HeLa cells ( Figure  4c (e) Average total chromosomal gaps and breaks per cell in HCT15 following transfection with CHK2 siRNA compared to control siRNA and untransfected HCT116 in the absence (black bars) or presence of 0.1 mM APH (grey bars); n ¼ 100 metaphases for each data set. (f) Frequency (%) of gaps and breaks at specific fragile sites FRA3B and FRA16D in HCT15 and HCT116 cells following transfection of CHK2 siRNA compared to control siRNA in the absence (black bars) or presence of 0.1 mM APH (grey bars); n ¼ 100 sites examined. Frequency of fragile site breakage is presented as the percentage of chromosome 3 or chromosome 16 homologs with breaks at FRA3B or FRA16D, respectively. All error bars indicate the 95% confidence interval.
CHK1 regulates fragile site stability SG Durkin et al are both detected indistinguishably by the TUNEL assay. We reasoned that detection of DNA strand breaks in apoptosis-inhibited CHK1-depleted cells would suggest that the highly fragmented and broken chromosomes seen in CHK1-depleted cells were occurring independently of apoptosis. We observed positive TUNEL staining in CHK1-depleted cells confirming the presence of DNA strand breaks (Figure 4d ). These breaks were not eliminated by ZVAD-fmk treatment suggesting they were not a result of nuclear fragmentation that occurs during the late stages of apoptosis (Figure 4d ). We further confirmed these results by analyzing metaphase chromosome spreads of duplicate samples, which were assessed for fragmented chromosomes. Approximately 58% of HCT116 and 60% of HeLa CHK1-depleted metaphases, and none of the CHK1-proficient siControl RNA treated metaphases, had severely fragmented chromosomes exceeding 100 gaps and breaks ( Figure  4e and f). This percentage decreased only minimally with the addition of ZVAD-fmk, to 51 and 52%, respectively, indicating that apoptosis did not significantly contribute to the observed severe chromosome instability ( Figure  4e and f) (HCT116 P ¼ 0.42, HeLa P ¼ 0.42).
CHK1 and CHK2 are phosphorylated at doses of APH that induce fragile site breakage Phosphorylation of the CHK1 and CHK2 kinases is required for their activation and the subsequent regulation of their downstream targets (reviewed in Bartek and Lukas, 2003) and in the case of CHK1 proteolytic degradation under some genotoxic conditions (Zhang et al., 2005) . We, therefore, investigated the effects of low doses of APH that induce fragile site breakage, but do not completely inhibit the process of replication, on the phosphorylation of both CHK1 and CHK2 using antibodies raised against their phosphorylated isoforms. HGMDFM090 (090) normal primary fibroblasts and HCT116 cells were exposed to varying doses of APH for 24 h, after which whole cell lysates were prepared and Western blotted. A dose-dependent increase in the phosphorylation of CHK1 was observed following APH treatment in both primary 090 fibroblasts and HCT116 cells, as determined by probing with antiphospho CHK1 Ser 317 and antiphospho CHK1 Ser 345 antibodies (Figure 5a ). Phosphorylation of these residues following a low dose (0.1 mM) APH treatment for 24 h suggests that CHK1 is active under conditions of replication stress that induce fragile site breakage. Similar CHK1 phosphorylation patterns were observed for both normal fibroblast and HCT116 colon cancer cell lines assayed (Figure 5a ). The CDC25A phosphatase is a shared substrate of CHK1 and CHK2 whose expression is modulated by ubiquitination and degradation following DNA damage, eliciting a checkpoint response (Mailand et al., 2000 (Mailand et al., , 2002 Falck et al., 2001 Falck et al., , 2002 Sorenson et al., 2003) . At the lowest dose of APH, we did not observe a significant decrease in CDC25A levels, consistent with the hypothesis that low levels of replication inhibition would not induce a complete checkpoint arrest (Figure 5b ). However, at higher doses of APH, levels of CDC25A degradation consistent with checkpoint activation were observed. In addition, using antiphospho CHK2-Thr 68 and anti-phospho CHK2-Thr 387 antibodies, we observed a dose-dependent increase in CHK2 phosphorylation following APH treatment indicating that CHK2 is also activated at concentrations of APH that induce fragile site breakage (Figure 5c ).
Discussion
The CHK1 kinase has broad roles in monitoring the progression of DNA replication. Here, we present evidence describing a critical requirement for the CHK1 kinase in maintaining chromosome stability, and specifically the stability of common fragile site regions. These data are consistent with our earlier finding that an ATR-regulated pathway is critical for maintaining fragile site stability (Casper et al., 2002 . Following depletion of CHK1 by siRNA, five to seven percent of total chromosomal gaps and breaks in scoreable cells were calculated to occur at just two fragile sites, FRA3B and FRA16, both spontaneously and with APH treatment, demonstrating the particular sensitivity of common fragile sites to CHK1 deficiency. Given that over 80 common fragile sites have been described, with B80% of breaks occurring at just 20 sites in normal cells (Glover et al., 1984) , it is likely that the majority of gaps and breaks in these cells occurred at common fragile sites.
We observed varying degrees of chromosome breakage in cells depleted for CHK1. Approximately 60% of CHK1-depleted cells exhibited extensive chromosome fragmentation, defined as >100 breaks per cell, and following APH treatment, these numbers rose to 80-95% of cells. The remainder of cells exhibited discrete numbers of chromosome breaks ranging widely from zero to 100 breaks per individual cell. The extent of chromosome breakage observed in CHK1 depleted cells most likely reflects the stage of the cell cycle at which depletion of CHK1 is maximal and is consistent with the asynchronous nature of DNA replication. Discrete numbers of chromosome gaps and breaks on metaphase chromosomes may represent cells depleted for CHK1 in late S-phase when the genome is nearly completely replicated. Here breaks would appear at late replicating regions or regions where replication origins are maximally spaced. This is consistent with the hypothesis that fragile sites are regions that initiate replication late in S-phase and are subject to further delay with the addition of replication inhibitors (Le Beau et al., 1998) .
In contrast, extensive chromosome fragmentation may represent cells maximally depleted of CHK1 during early S-phase. This extensive chromosome fragmentation phenotype is consistent with the gross chromosomal instability phenomenon observed by Syljuasen et al., 2005 in CHK1-depleted cells. Here, it was proposed that the extreme chromosome fragmentation resulted from a requirement for CHK1 in the initiation of DNA replication and in the inhibition of ectopic replication origin activation (Syljuasen et al., 2005) . Additionally, there is evidence that CHK1 is required to block late origin firing, prevent early mitotic entry and maintain viable replication fork structures when DNA synthesis is inhibited with APH, consistent with our observations (Takai et al., 2000; Feijoo et al., 2001; Zachos et al., 2003 Zachos et al., , 2005 .
We have further determined that the extensive chromosome fragmentation observed in CHK1-depleted cells is not the result of late-stage apoptotic endo- CHK1 regulates fragile site stability SG Durkin et al nucleolytic cleavage. Treating CHK1-depleted cells with the pan-caspase inhibitor ZVAD-fmk to inhibit apoptosis did not result in decreased chromosome breakage as assessed by both TUNEL and standard metaphase analysis. Similar studies of apoptosis in CHK1-depleted cells have been performed, supporting these results (Syljuasen et al., 2005) . Also in agreement with these findings, Alderton et al. (2004) have reported that in cells from patients with Seckel syndrome, an HUinduced nuclear fragmentation phenotype is independent from apoptosis (Alderton et al., 2004) . The proposed roles for CHK1 in maintaining replication fork integrity during S-phase in response to replication inhibition and during normal cell cycles could explain the severe chromosome fragmentation phenotype that we observed in a subset of CHK1-depleted cells.
Increased fragile site breakage in CHK1-depleted cells is also likely to result from a loss of the CHK1-dependent G2/M response. This hypothesis is consistent with previous findings that BRCA1 is required for activating the CHK1 kinase to regulate DNA damageinduced G2/M arrest (Yarden et al., 2002) . Furthermore, our laboratory demonstrated that BRCA1-null cells ectopically expressing BRCA1 mutated at serine 1423, which is deficient in the G2/M checkpoint, show increased fragile site instability at levels comparable to those seen in BRCA1-null cells (Xu et al., 2001; Arlt et al., 2002) . These results strengthen the hypothesis that fragile sites are late replicating regions that may be subject to G2/M checkpoint regulation following entry into G2 with incompletely replicated DNA (Le Beau et al., 1998) .
Consistent with our data showing the importance of CHK1 in maintaining chromosome and fragile site stability, we observed the dose-dependent phosphorylation of CHK1 at residues Ser 317 and Ser 345 at concentrations of APH that induce fragile site breaks. Interestingly, at these same doses, we also observed the phoshorylation of CHK2 at residue Thr 68 and at residue Thr 387 . Activation of CHK2 at these APH concentrations suggests that CHK2 may respond to a downstream event resulting from replication stalling, such as the generation of double strand breaks. However, our data indicates that CHK2 is not required for preventing chromosome and fragile site instability. This is in agreement with previous studies that have demonstrated a central role for CHK1 rather than CHK2 in responding to the bulk of stalled replication forks (Feijoo et al., 2001) . A recent study showing increased fragile site instability following downregulation of the homologous recombination and non-homologous end joining proteins RAD51, LIG4, and DNAPKcs implicates double-strand break repair pathways in the regulation of fragile site stability (Schwartz et al., 2005) . Such breaks are likely to be a consequence of stalled or incomplete replication in fragile site regions.
The results presented here demonstrate a critical role for CHK1 in regulating the stability of common fragile sites. These data build on earlier studies where other members of the ATR pathway, such as BRCA1 and FANCD2, have been implicated in maintaining fragile site stability Howlett et al., 2005) , and are consistent with the hypothesis whereby common fragile fragile sites represent loci prone to replication fork stalling or collapse (Casper et al., 2002; Glover et al., 2005) . Recent findings demonstrating that common fragile sites can serve as markers of DNA replication stress during early stages of tumorigenesis (Bartkova et al., 2005; Gorgoulis et al., 2005) highlight the importance of understanding the molecular pathways that regulate fragile site stability.
Materials and methods
Cell lines and culture conditions HCT116, HeLa, HCT15 and 090 primary fibroblasts were cultured in DMEM supplemented with 10% FBS.
Chromosome analysis and FISH Cells were exposed to 0.1-0.3 mM APH for 24 h prior to harvest. Harvesting of cells, chromosome preparations, and FISH protocols using YAC 850a6 to detect FRA3B and BAC264L1 to detect FRA16D, were performed as previously described (Wilke et al., 1996 .
RNAi siRNA sequence pools targeted against CHK1 and CHK2 and a non-targeting siRNA control pool were purchased from Dharmacon Inc. (Lafayette, CO, USA). Transfections were performed with Oligofectamine (Invitrogen Inc., Carlsbad, CA, USA) according to the manufacturer's instructions (Dharmacon Inc.).
Western blots
Cell lysates were prepared by resuspending cell pellets in RIPA buffer and incubating on ice for 30 min. Bio-Rad Tris-HCl Ready Gels and NuPAGE Bis-Tris gels were used to resolve proteins. Whole-cell lysate (40 mg) was loaded per lane. Gels were transferred to PVDF membrane (Millipore Inc., Billerica, MA, USA) using a Trans-Blot s.d. Semi-Dry Transfer system (Bio-Rad Laboratories, Hercules, CA, USA). Antibody hybridization and chemiluminescence detection were performed according to standard protocols. CHK1 protein was detected with sc-8408 (Santa-Cruz Biotechnology Inc., SantaCruz, CA, USA), CHK2 protein was detected with ab8108 (Novus Biologicals, Littleton, CO, USA), CHK1 Ser 345 was detected with Phospo-Chk1 (Ser345) (Cell Signaling Technology Inc., Danvers, MA, USA), CHK1 Ser 317 was detected with Phosho-Chk1 (Ser317) (Cell Signaling), CDC25A was detected with aCdc25A-DCS120 (Upstate Biotechnology), CHK2 Thr 68 was detected with Phospho-Chk2 (Thr68) (Cell Signaling), and CHK2 Thr 387 was detected with Phospho-Chk2 (Thr387) (Cell Signaling). HRP-conjugated anti-mouse and anti-rabbit antibodies were obtained from Amersham Biosciences, Piscataway, NJ, USA.
Terminal deoxynucleotidyl transferase biotin-dUTP nick end labeling assay Cells were fixed in 4% w/v paraformaldehyde at 41C and permeabilized in 0.1% Triton X-100 in PBS. Terminal deoxynucleotidyl transferase biotin-dUTP nick end labeling assay was then performed according to the manufacturer's instructions (Roche In Situ Cell Death Detection Kit Fluorescein). Following washes, cells were counterstained with Vectashield and examined with a Zeiss Axioscope epifluorescence microscope and imaged with Olympus DP70 digital camera system.
Apoptosis and flow cytometry analysis
Cells were harvested and Alexa Fluor 488 annexin V/ propidium iodide apoptosis assay was performed according to the manufacturer's instructions (Molecular Probes Vybrant Apoptosis Assay Kit #2). Flow cytometric analysis (Coulter Elite ESP Cell Sorter) was performed to determine the proportion of annexin V positive cells in each sample.
Statistical analysis
Total Gaps and breaks data were analysed using the Student's t-test for equal or unequal variance. Variance for each data set was determined using the sample variance F-test. Fisher's two-sided exact test was used for analysis of specific fragile site expression data.
